Drugs / CEP-9722
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01345357 | May 2011 → Dec 2012 | mantle cell lymphoma | Cephalon | Completed | No outcome recorded |
| Phase 1 | NCT00920595 | Jun 2009 → Oct 2011 | cancer | Cephalon | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01311713 | May 2011 → Oct 2013 | cancer | Teva Branded Pharmaceutical Products R&D, Inc. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CEP-9722 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01345357 ↗ |
| Action | Inhibit | “CEP-9722 (a PARP-1 and PARP-2 Inhibitor)” NCT00920595 ↗ |
| Modality | Small molecule | — CHEMBL4297461 ↗ |
| Route | Oral | “CEP-9722 tablets twice daily (BID) orally” NCT01311713 ↗ |